NanoViricides Inc: Rises on selecting COVID-19 drug candidate

NanoViricides,

16/09/2020 12:57

** Antiviral drug developer's shares  NNVC.A  rise 6.4% to
$4.8 premarket 
    ** Late on Tuesday, co said it has selected a drug candidate
for the treatment of COVID-19  urn:newsml:reuters.com:*:nEQ4TQgHka
    ** NV-CoV-1 is designed to attack the virus particles
themselves, and possibly would also attack infected cells - NNVC
    ** Says its drug candidate, NV-CoV-1-R, has Gilead Sciences
Inc's  GILD.O  remdesivir encapsulated inside the core
    ** Up to Tuesday's close, stock had risen ~81% YTD 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))